From severe arthritis to neurological damage, “Chikungunya” is more than a fever. It’s a molecular challenge demanding molecular solutions.
Arthropod-borne viruses (arboviruses) such as Dengue, Zika, West Nile, Yellow fever—and more recently, Chikungunya virus (CHIKV)—pose a growing threat to human health worldwide. Transmitted primarily by mosquitoes, these viruses can cause anything from flu-like symptoms to severe complications, including arthritis, encephalitis, and neurological disorders.
In July 2025, new cases of chikungunya fever were reported across Guangdong Province, with the WHO issuing a global alert on the potential for widespread outbreaks. With CHIKV now reported in 119 countries and regions, the risk of escalation is clear.
At the molecular level, CHIKV depends on the E1 and E2 structural proteins, which form the viral spikes essential for receptor binding and membrane fusion. These proteins—particularly the conserved E2—are also key targets for neutralizing antibodies, making them critical markers for diagnostics, vaccine development, and antiviral strategies.
At Sino Biological, we recognize the urgency of preparing for outbreaks like CHIKV. In response to the newly reported variants (UVE/CHIKV/2024/RE/CNR_79903), we have rapidly launched recombinant E1 and E2 proteins, as well as antibodies, to support global researchers. Alongside our comprehensive arbovirus antibody collection, these tools are designed to accelerate the development of diagnostics, therapeutics, and vaccines to combat arboviral diseases.
With arboviruses on the rise, reliable research tools are no longer optional—they are essential.
Explore our CHIKV research tools: https://ow.ly/AfoN50WySA5
